A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 912 participants.
Also called NCT07417306
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 912 participants
- Registry
-
NCT07417306
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07417306. Randomized; no masking; primary purpose treatment. Start 2026-03-27 (anticipated); primary completion 2027-08-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- HDM1005 1
- Intervention (Drug)
- HDM1005 2
- Intervention (Drug)
- Mazdutide
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07417306- Content hash
fbc1d483e0dd510092e90ae831b9c2565364bcbc7e71ec1124021a4d5855734f